Prevalence of Acromegaly in a Diagnostic Consultation for Sleep Apnea Syndrome

Not Applicable

Completed

• Conditions: Sleep Apnea Syndrome
• Interventions: Other: Diagnosis of acromegaly

• Registration Number: NCT02789696
• Lead Sponsor: University Hospital, Grenoble

Brief Summary

Prevalence of sleep apnea syndrome in patients with acromegaly is about 70%. It seems that comorbidities of arterial hypertension or type 2 diabetes are more severe in patients with acromegaly and sleep apnea syndrome. Besides sleep apnea syndrome associated to acromegaly gives rise to few symptoms, that explains it is under diagnosed. The mechanisms of the association are based on maxillofacial modifications linked to acromegaly, a thickening of soft tissues with deposits of glyco-aminoglycanes but probably also because of the associated obesity, of the potential existence of a goiter and a muscular dystrophy of the dilatative muscles of the pharynx.

At present, no study clearly documented prevalence of acromegaly in a diagnostic consultation for sleep apnea syndrome.

Detailed Description

60 investigators will participate to this study. They will be chosen among those participating to the sleep observatory of the federation of pneumology (www.osfp.fr).

All participating pneumologists would have to fill in the questionnaire (co-morbidities, concomitant treatments, biological analysis) directly online and also clinical signs and symptoms of acromegaly. A blood test for the insulin-like growth factor (IGF-1) dosage will be systematically prescribed to the patient. Pneumologists will have to include all consecutive patients presenting with sleep apnea syndrome suspicion.

According to first IGF-1 results, patients may have to do a second blood test in a referenced laboratory to confirm the dosage.

Study Timeline

• Study Start: 2013-11
• Primary Completion: 2014-10
• Study Completion: 2016-05
• Study First Submitted: 2016-05-11
• Study First Submitted QC: 2016-06-02
• Study First Posted: 2016-06-03
• Status Verified: 2020-03
• Last Update Submitted: 2020-03-19
• Last Update Posted: 2020-03-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 880

Inclusion Criteria

• Body mass index < 40 kg/m2
• Patient consulting for sleep breathing disorder
• Informed consent signed
• patient covered by french health insurance

Exclusion Criteria

• Other sleep disorder already diagnosed
• Pregnant women
• Patients participating in an other study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Acromegaly	Diagnosis of acromegaly	Diagnosis of acromegaly

Primary Outcome Measures

Name	Time	Method
determination of acromegaly prevalence	1 year	IGF-1 (insulin-like growth factor-1) quantification in blood punction

Secondary Outcome Measures

Name	Time	Method
description of clinical signs of acromegaly associated to sleep apnea syndrome (Epworth scale)	1 year	Score to Epworth scale will be compared between patients with sleep apnea syndrome with acromegaly and patients with sleep apnea syndrome only.

Trial Locations

Locations (1)

University Hospital Grenoble; 🇫🇷 Grenoble, Isère, France